首頁
Therapeutics Incorporated

8月 2026Therapeutics Incorporated的市場佔有率分析

Therapeutics, Inc., the dermatology CRO authority, navigates the complex maze of non-clinical, clinical, and regulatory hurdles to deliver integrated, turnkey solutions built for your unique requirements, from concept to commercialization. Learn more.

行業: N/A

域名therapeuticsinc.com

成立年份1985

僱員51 - 200

年度營收$15M - $25M

Therapeutics Incorporated

Therapeutics Incorporated（包含公司地區）

therapeuticsinc.com

查看更多網站流量與參與度資訊

Therapeutics Incorporated截至 8月 2026 的總收入為 15M - 25M

Therapeutics Incorporated 熱門網域產生的總收入

Therapeutics Incorporated 熱門網域 3 年內的總收入

Therapeutics Incorporated 熱門網域的總收入

therapeuticsinc.com15M - 25M

透過銷售情報查看更多內容

Therapeutics Incorporated的熱門網域總造訪量

了解Therapeutics Incorporated市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

therapeuticsinc.com--

透過銷售情報查看更多內容

Therapeutics Incorporated的熱門網域平均造訪時長

分析Therapeutics Incorporated參與度指標。

過去 3 個月平均造訪時長

子公司細目

therapeuticsinc.com--

透過銷售情報查看更多內容

Therapeutics Incorporated的熱門網域平均頁面瀏覽量

了解Therapeutics Incorporated如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

therapeuticsinc.com--

透過銷售情報查看更多內容

Therapeutics Incorporated按網域劃分的熱門競爭對手

看起來這裡的數據不足

無可顯示數據

使用的熱門技術Therapeutics Incorporated

这些是Therapeutics Incorporated顶级域名使用的行业网站技术

小工具 (3)

Twemoji

內容管理系統 (2)

WordPress

市場行銷 (2)

Google Marketing Platform

行動裝置 (2)

Meta Viewport

更多技術

5

檢視所有

新聞與訊號來自Therapeutics Incorporated

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Therapeutics, Inc. attended event International Conference on Jan 1st '25.Somaiya Vidyavihar University, a legacy educational institute, has announced the International Conference on Clinical Translation of Biomaterial-based Therapeutics and Devices (ICBTD 2025).

新聞Therapeutics, Inc. hires Jan Case as Chief Operating Officer.NEWARK, Del.-(BUSINESS WIRE)-#CRISPR-CorriXR Therapeutics, Inc., a pioneering biotherapeutics company focused on oncology and innovative technologies to overcome drug resistance in solid tumors, announced that Jan Case has joined the Company as Chief Operating Officer.

新聞Therapeutics, Inc. is developing first-in-class, next-generation medicines for cardiometabolic diseases on Dec 19th '24.SAN FRANCISCO-(BUSINESS WIRE)-Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardiometabolic diseases, today announced additions to its management team and board of directors.